Patent · US Active

Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors

US10556908B2 · kind B2 · utility

8Cited by

25References

37Claims

0Family size

Assignee

Incyte Corporation · US

Inventors

Liangxing Wu · Wilmington, US
Joel R. Courter · Glen Mills, US
Chunhong He · Boothwyn, US
Jingwei Li · Beijing, CN
Liang Lu · Hockessin, US
Yaping Sun · Lexington, US
Xiaozhao Wang · Readington, US
Wenqing Yao · Kennett Square, US
Colin Zhang · Ambler, US
Jincong Zhuo · Boothwyn, US

Key dates

Filing date	Sep 13, 2018
Grant date	Feb 11, 2020
Priority date	—
Expiry date	Sep 13, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D519/00
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The present invention is directed to imidazo[1,2-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.